Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Restructuring Costs (2024 - 2025)

Lyra Therapeutics has reported Restructuring Costs over the past 2 years, most recently at $238000.0 for Q4 2025.

  • Quarterly results put Restructuring Costs at $238000.0 for Q4 2025, down 85.54% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (down 86.1% YoY), and the annual figure for FY2025 was $1.5 million, down 86.24%.
  • Restructuring Costs for Q4 2025 was $238000.0 at Lyra Therapeutics, up from -$21000.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for LYRA hit a ceiling of $6.4 million in Q2 2024 and a floor of -$21000.0 in Q3 2025.